Intellia says in-body CRISPR therapy lonvo-z still works at four years

Intellia says in-body CRISPR therapy lonvo-z still works at four years

Intellia Therapeutics, a company headquartered in Cambridge, Massachusetts, has released data indicating that its gene-editing therapy lonvoguran ziclumeran, known as lonvo-z, continues to be effective four years after treatment. Nature reports the result.

Lonvo-z was designed to treat one form of a genetic condition, a type of hereditary angioedema, that can cause episodes of painful and potentially dangerous swelling in the throat and other parts of the body. It uses the CRISPR-Cas9 gene-editing system to disable the gene that produces prekallikrein, a protein made in the liver that promotes blood-vessel leakage.

Intellia has applied for approval of lonvo-z by the US Food and Drug Administration, which is expected to issue a decision by 10 March. On 12 November, chief executive John Leonard told investors that if approved, the therapy will become the world's first CRISPR medicine delivered directly inside the body, or in vivo. Today, the only CRISPR therapy approved by the FDA works on cells that have been removed from the body and are then re-infused.

Jonathan Bernstein, a hereditary-angioedema specialist at the University of Cincinnati in Ohio and an investigator on a lonvo-z trial, says the approach could offer people with the condition relief from a lifetime of juggling medications to prevent and treat swelling attacks. Of the four-year data he says: "It’s very reassuring. That’s what you’re supposed to see."

The contrast is with Casgevy, the only approved CRISPR therapy, which treats two genetic blood disorders, sickle-cell disease and β-thalassaemia. To make a dose, physicians remove blood stem cells from the recipient and send them off for gene editing before infusing them back. Each dose must be made anew for each person, which adds time, cost and complexity, and the recipient has to undergo harsh chemotherapy to make room for the edited cells.

In vivo approaches aim to sidestep this by editing genes inside the body. Lonvo-z consists of fatty particles that encase mRNA encoding CRISPR-Cas9 components. The particles are infused into the blood and taken up by the liver, where prekallikrein is produced. The procedure takes one day.

Nature also notes the drawbacks. In vivo editing affords no opportunity to screen out cells with unwanted edits at other locations in the genome, and recipients might have harmful immune responses. Last year the FDA placed a clinical hold on two of Intellia's in vivo trials for a different disorder, after a participant with additional health conditions developed signs of liver damage and died after receiving a CRISPR treatment. The FDA lifted the hold this year after extra safety measures were added.

Key facts

  • Intellia Therapeutics says lonvo-z (lonvoguran ziclumeran) continues to be effective four years after treatment, according to data it released.
  • The FDA is expected to decide on lonvo-z by 10 March; CEO John Leonard told investors on 12 November that approval would make it the first CRISPR medicine delivered inside the body.
  • Lonvo-z uses CRISPR-Cas9 to disable the liver gene for prekallikrein, in a one-day procedure using fatty particles carrying mRNA.
  • The only FDA-approved CRISPR therapy today, Casgevy, edits cells outside the body, must be made anew for each person and requires harsh chemotherapy.
  • Last year the FDA put a clinical hold on two Intellia in vivo trials for a different disorder after a participant died; the hold was lifted this year after extra safety measures.

Why it matters

If the FDA approves lonvo-z, it would be the first CRISPR medicine delivered directly inside the body, according to Intellia's chief executive. The only approved CRISPR therapy so far, Casgevy, requires removing a patient's blood stem cells, editing them elsewhere, and infusing them back after chemotherapy. Lonvo-z skips that: fatty particles carrying mRNA are infused into the blood, taken up by the liver, and the procedure takes one day. A four-year result is the longer-term evidence that the edit holds.

Who it affects

Primarily people with this form of hereditary angioedema, who currently juggle medications to prevent and treat swelling attacks in the throat and elsewhere. Bernstein says gene editing could offer relief from that. More broadly, it concerns developers of in vivo gene-editing therapies, since, if approved, lonvo-z would be the first in vivo CRISPR medicine, according to Intellia's chief executive.

How to use it

This is not something patients or clinicians can use yet. Lonvo-z is awaiting an FDA decision expected by 10 March. If approved, it would be given as a one-day infusion of fatty particles that deliver CRISPR-Cas9 instructions to the liver. Patients with the condition would need to ask their specialists about eligibility once a decision is made.

How solid is it

The four-year result comes from data released by the developer, Intellia, and is relayed by Nature with comment from Bernstein, an investigator on a lonvo-z trial, so the source of the data and the commentator are both involved in the work. The source does not give efficacy figures or participant numbers for the four-year data. It also does not say whether the data are peer-reviewed. The first-in-vivo claim is Leonard's statement to investors and is conditional on approval.

Risks and caveats

In vivo editing can introduce safety concerns: there is no chance to screen out cells with unwanted edits at other places in the genome, and recipients might have harmful immune responses. Last year the FDA put a clinical hold on two Intellia in vivo trials for a different disorder, after a participant with additional health conditions developed signs of liver damage and died after receiving a CRISPR treatment. The hold was lifted this year after extra safety measures were added. An FDA decision is still pending, and approval is not assured.

“It’s very reassuring”

— Jonathan Bernstein, hereditary-angioedema specialist at the University of Cincinnati and investigator on a lonvo-z trial, on the four-year data